Axon Enterprise, Inc $AXON Shares Bought by SHEPHERD WEALTH MANAGEMENT Ltd LIABILITY Co

SHEPHERD WEALTH MANAGEMENT Ltd LIABILITY Co grew its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 70.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,829 shares of the biotechnology company’s stock after purchasing an additional 1,165 shares during the period. Axon Enterprise makes up approximately 1.4% of SHEPHERD WEALTH MANAGEMENT Ltd LIABILITY Co’s investment portfolio, making the stock its 18th largest holding. SHEPHERD WEALTH MANAGEMENT Ltd LIABILITY Co’s holdings in Axon Enterprise were worth $2,030,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of AXON. Westside Investment Management Inc. increased its stake in Axon Enterprise by 4.8% during the 2nd quarter. Westside Investment Management Inc. now owns 283 shares of the biotechnology company’s stock valued at $225,000 after buying an additional 13 shares during the period. CVA Family Office LLC lifted its position in Axon Enterprise by 26.9% in the second quarter. CVA Family Office LLC now owns 66 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 14 shares during the period. Newbridge Financial Services Group Inc. increased its position in shares of Axon Enterprise by 2.8% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 508 shares of the biotechnology company’s stock valued at $421,000 after purchasing an additional 14 shares during the period. Vicus Capital raised its stake in shares of Axon Enterprise by 3.7% in the 3rd quarter. Vicus Capital now owns 396 shares of the biotechnology company’s stock worth $284,000 after buying an additional 14 shares in the last quarter. Finally, Evergreen Capital Management LLC lifted its holdings in shares of Axon Enterprise by 3.8% in the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock valued at $342,000 after buying an additional 15 shares during the period. 79.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have commented on AXON. JMP Securities reiterated a “market outperform” rating and issued a $825.00 price target on shares of Axon Enterprise in a research report on Monday, September 29th. UBS Group decreased their price target on shares of Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 5th. Zacks Research downgraded Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 2nd. Wall Street Zen lowered Axon Enterprise from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Finally, The Goldman Sachs Group cut their target price on Axon Enterprise from $940.00 to $800.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Fourteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $802.71.

Axon Enterprise Stock Performance

AXON stock opened at $591.15 on Thursday. The firm has a 50 day simple moving average of $602.67 and a 200 day simple moving average of $703.63. Axon Enterprise, Inc has a 52 week low of $469.24 and a 52 week high of $885.91. The stock has a market cap of $46.65 billion, a P/E ratio of 187.07, a P/E/G ratio of 135.74 and a beta of 1.40. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.89 and a current ratio of 3.12.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). The company had revenue of $710.64 million for the quarter, compared to analyst estimates of $704.83 million. Axon Enterprise had a net margin of 10.05% and a return on equity of 4.29%. The company’s quarterly revenue was up 30.6% on a year-over-year basis. During the same period last year, the business earned $1.45 EPS. Research analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, CEO Patrick W. Smith sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $551.92, for a total transaction of $5,519,200.00. Following the completion of the sale, the chief executive officer owned 3,110,997 shares of the company’s stock, valued at $1,717,021,464.24. This represents a 0.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Jennifer H. Mak sold 1,134 shares of the business’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $600.00, for a total transaction of $680,400.00. Following the completion of the sale, the chief accounting officer owned 13,740 shares of the company’s stock, valued at $8,244,000. The trade was a 7.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 65,540 shares of company stock worth $39,201,438 in the last 90 days. Company insiders own 4.40% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.